

April 2006

Issue 29

Headlines:

- MRC funding
- ESC investigators meeting
- Day 7 forms

**Current
Recruitment**
469



Congratulations to Doctor Wong and team at Prince of Wales Hospital, Hong Kong who recruited their first patient this month



ENOS Trial Office

enos@nottingham.ac.uk

Tel +44 115 823 1769

Fax. +44 115 823 1771

Chief Investigator

Philip Bath

+44 115 823 1023

Trial Medic

Nikola Sprigg

+44 115 823 1769

Clinical Trials Nurse

Helen Stear

+44 115 823 1770

Trial Statistician

Laura Gray


+44 115 823 1772

CT Coordinator

Lida Kaur

+44 115823 1776

ENOS NEWS



The Newsletter for the 'Efficacy of Nitric Oxide in Stroke' Trial

MRC funding

We are delighted to announce that ENOS has been awarded full funding from the Medical Research Council (MRC), UK. This grant will fund the main phase of the trial and will provide support for the increase in trial centres needed to meet the target of 5000 patients. More centres are due to start in Australia, China, India, Italy and New Zealand and we welcome any other potential new sites or investigators.

Investigators Meeting

We are pleased to invite investigators attending the European Stroke Conference in Brussels in May to join us for an Investigators Meeting at the Brussels Exhibition Center, Thursday, May 18, 2006 13.30 - 14.00 Room 1125 in the congress centre. Our colleagues from CLOTS and VITATOPS will also be presenting at this meeting and refreshments will be provided.

Day 7 Case Report Forms

The day 7 case report form has now been changed so that investigators can more easily record adverse events during the treatment period. Investigators are now specifically asked to records TIA's and neurological deterioration. Neurological deterioration is defined in the protocol as fall in Scandinavian Neurological Stroke Scale of 5 points or more and to aid investigators a reminder of the patients SNSS baseline score will be shown as a prompt prior to completing the day 7 SNSS. Investigators will also be asked to record if blood samples have been taken; EDTA and serum day 0 and serum day 7.

Tips of the month

Investigators are reminded that patients with renal or hepatic impairment are at risk of precipitous falls in blood pressure when treated with antihypertensive medications. Patients with severe renal or hepatic impairment, i.e. those who require replacement therapy should not be considered for inclusion into the trial. The proportion of patients in the stop continue arm has fallen below 50%. Investigators are reminded to enrol patients on prior antihypertensive medication in order to answer the important question of how to manage these patients.

******* ENOS now has 29 centres in 9 countries*******
More centres are welcome
Please join us